Literature DB >> 18050362

Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report.

Farrah J Mateen1, Aminah Jatoi, Timothy W Lineberry, Dawn Aranguren, Edward T Creagan, Gary A Croghan, James R Jett, Randolph S Marks, Julian R Molina, Ronald L Richardson.   

Abstract

OBJECTIVE: Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia.
METHODS: This retrospective study focused on patients with pre-existing schizophrenia (or in some instances schizoaffective disorder) and a lung cancer diagnosis made between 1980 and 2004. 'Disparity' was defined as a patient's having been prescribed less aggressive therapy for a potentially curable cancer based on state-of-the-art treatment standards for the time and for the cancer stage. Qualitative methods were used to assess healthcare providers' decision-making.
RESULTS: 29 patients were included. The median age was 59 years; 38% were men. Twenty-three had non-small cell lung cancer and 6 small cell lung cancer; 17 had potentially curable cancers. Five of 17 had a 'disparity' in cancer care: (1) no cancer therapy was prescribed because of chronic obstructive pulmonary disease; (2) no cancer therapy was prescribed because of infection; (3) no chemotherapy was prescribed because the patient declined it; radiation was provided; (4) no chemotherapy was prescribed because of the patient's schizophrenia symptoms; radiation was administered; and (5) no surgery was performed because of disorientation from a lobotomy; radiation was prescribed. Comments from healthcare providers suggest reflection and ethical adjudication in decision-making.
CONCLUSION: Schizophrenia was never the sole reason for no cancer treatment in patients with potentially curable lung cancer. This study provides the impetus for others to begin to assess the effect of schizophrenia on lung cancer management in other healthcare settings. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18050362      PMCID: PMC2715919          DOI: 10.1002/pon.1303

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  13 in total

Review 1.  Qualitative research in health care. Analysing qualitative data.

Authors:  C Pope; S Ziebland; N Mays
Journal:  BMJ       Date:  2000-01-08

2.  Mental disorders and use of cardiovascular procedures after myocardial infarction.

Authors:  B G Druss; D W Bradford; R A Rosenheck; M J Radford; H M Krumholz
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

Review 3.  Nicotine for schizophrenia.

Authors:  S Punnoose; M R Belgamwar
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

4.  Unforeseen inpatient mortality among veterans with schizophrenia.

Authors:  Laurel A Copeland; John E Zeber; Robert A Rosenheck; Alexander L Miller
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

5.  The role of psychiatric diagnosis in satisfaction with primary care: data from the department of veterans affairs.

Authors:  Rani A Desai; Elina A Stefanovics; Robert A Rosenheck
Journal:  Med Care       Date:  2005-12       Impact factor: 2.983

6.  Staging and prognostic factors in small cell carcinoma of the lung.

Authors:  K Osterlind; D C Ihde; D S Ettinger; R J Gralla; K Karrer; S Krauss; L H Maurer; M Rørth; S Sörenson; R Vincent
Journal:  Cancer Treat Rep       Date:  1983-01

7.  Appendectomy for appendicitis in patients with schizophrenia.

Authors:  Brian K Cooke; Louis T Magas; Katherine S Virgo; Bernard Feinberg; Adit Adityanjee; Frank E Johnson
Journal:  Am J Surg       Date:  2007-01       Impact factor: 2.565

8.  A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.

Authors:  Jose de Leon; Francisco J Diaz
Journal:  Schizophr Res       Date:  2005-07-15       Impact factor: 4.939

9.  Long-term outcome of major psychoses. II. Schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group.

Authors:  M T Tsuang; G M Dempsey
Journal:  Arch Gen Psychiatry       Date:  1979-11

10.  A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer.

Authors:  R T Eagan; T R Fleming; S Frytak; E T Creagan; J N Ingle; L K Kvols
Journal:  Cancer Treat Rep       Date:  1980-01
View more
  6 in total

1.  Inequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study.

Authors:  Cara Bergamo; Keith Sigel; Grace Mhango; Minal Kale; Juan P Wisnivesky
Journal:  Psychosom Med       Date:  2014-04       Impact factor: 4.312

2.  Outcome of patients with lung cancer and severe psychiatric disorder admitted to a medical psychiatric unit.

Authors:  Tomohiro Takehara; Tetsuo Tani; Hiroyuki Takiue; Ryo Takeshita; Arifumi Iwamaru; Tatsuya Yamamoto; Hidefumi Koh
Journal:  Mol Clin Oncol       Date:  2020-01-10

Review 3.  Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis.

Authors:  Alex J Mitchell; Oliver Lord
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

Review 4.  Inequalities in healthcare provision for people with severe mental illness.

Authors:  David Lawrence; Stephen Kisely
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

5.  Outcomes of surgery in lung cancer patients with schizophrenia.

Authors:  Toshiro Obuchi; Kan Okabayashi; Takayuki Imakiire; Satoshi Yoneda; Akinori Iwasaki
Journal:  Surg Today       Date:  2013-04-18       Impact factor: 2.549

6.  Cancer screening, prevention, and treatment in people with mental illness.

Authors:  Lara C Weinstein; Ana Stefancic; Amy T Cunningham; Katelyn E Hurley; Leopodo J Cabassa; Richard C Wender
Journal:  CA Cancer J Clin       Date:  2015-12-10       Impact factor: 508.702

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.